SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-024156
Filing Date
2024-03-20
Accepted
2024-03-19 20:41:52
Documents
16
Period of Report
2024-03-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0202127-8k_allarity.htm   iXBRL 8-K 43805
2 OPINION OF VENABLE LLP, DATED MARCH 19, 2024 ea020212701ex5-1_allarity.htm EX-5.1 6716
3 AT-THE-MARKET ISSUANCE SALES AGREEMENT, DATED MARCH 19, 2024, BY AND BETWEEN ALL ea020212701ex10-1_allarity.htm EX-10.1 224047
4 GRAPHIC ex5-1_001.jpg GRAPHIC 22278
  Complete submission text file 0001213900-24-024156.txt   540262

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE allr-20240319.xsd EX-101.SCH 3015
6 XBRL LABEL FILE allr-20240319_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE allr-20240319_pre.xml EX-101.PRE 22359
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0202127-8k_allarity_htm.xml XML 3736
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 24765976
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)